About
About SAMSUNG PHARM. Co., LTD
SAMSUNG PHARM. Co., LTD. manufactures and sells pharmaceutical products in South Korea. It offers prescription medicines, such as anticancer immunotherapy, antipyretic analgestic and antiinflammatory, antiobesity, hypotensive, antiarteriosclerotic, digestive organs, antophlegms, enzymes, ostepoposis, and transfusion agents, as well as skeletal muscle relaxants, anti-spastic, enzyme, mixed vitamins, antibiotics, and others. The company also provides medicines for the digestive system, medicines for liver disorders, medicines for the circulation system, cold medicines, nutritional supplements, health tonics, antophlegm agents, and others, as well as quasi-medicines, cold medicines, vitamins and energy drinks, and functional foods. The company was founded in 1929 and is headquartered in Hwaseong-si, South Korea.
Research context
SAMSUNG PHARM. Co., LTD appears in PyInvesting’s Korea Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- KRW
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Visit company website
5 years, 6 months ago
SAMSUNG PHARM. Co., LTD is currently in a long term uptrend where the price is trading 13.4% above its 200 day moving average.
From a valuation standpoint, the stock is 13.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 7.4.
SAMSUNG PHARM. Co., LTD's total revenue sank by 73.9% to $6B since the same quarter in the previous year.
Its net income has dropped by 229.2% to $-21B since the same quarter in the previous year.
Finally, its free cash flow grew by 25.2% to $-2B since the same quarter in the previous year.
Based on the above factors, SAMSUNG PHARM. Co., LTD gets an overall score of 3/5.